scholarly article | Q13442814 |
P356 | DOI | 10.1002/ANA.410430604 |
P698 | PubMed publication ID | 9629839 |
P50 | author | E. Tessa Hedley-Whyte | Q120721373 |
P2093 | author name string | Chen C | |
Cudkowicz ME | |||
Brown RH Jr | |||
McKenna-Yasek D | |||
P2860 | cites work | Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis | Q28131805 |
Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis | Q28303406 | ||
Superoxide dismutase in familial amyotrophic lateral sclerosis: models for gain of function | Q41111012 | ||
Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes | Q41187994 | ||
An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis | Q41194811 | ||
Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia | Q48596448 | ||
P433 | issue | 6 | |
P921 | main subject | copper | Q753 |
amyotrophic lateral sclerosis | Q206901 | ||
P304 | page(s) | 703-710 | |
P577 | publication date | 1998-06-01 | |
P1433 | published in | Annals of Neurology | Q564414 |
P1476 | title | Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene | |
P478 | volume | 43 |
Q35726226 | Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis |
Q58152648 | Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis |
Q40957607 | Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005-2015 update |
Q33839535 | Amyotrophic lateral sclerosis: copper/zinc superoxide dismutase (SOD1) gene mutations |
Q50902208 | An autopsy case of sporadic amyotrophic lateral sclerosis associated with the I113T SOD1 mutation. |
Q58181059 | An unusual case of familial ALS and cerebellar ataxia |
Q48147320 | Autosomal dominant juvenile amyotrophic lateral sclerosis |
Q33586412 | Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases |
Q82029139 | Chapter 5 Cytopathology of the motor neuron |
Q73128584 | Clinical characteristics of SOD1 gene mutations in UK families with ALS |
Q51718105 | Clinical features and neuropathological findings of familial amyotrophic lateral sclerosis with a His46Arg mutation in Cu/Zn superoxide dismutase. |
Q37274526 | Clinical neurogenetics: amyotrophic lateral sclerosis |
Q28198830 | Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS |
Q37189268 | Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis |
Q39710272 | Defining SOD1 ALS natural history to guide therapeutic clinical trial design |
Q34983540 | Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex |
Q36743954 | Diagnostic clues and more from photographs |
Q48357421 | Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex |
Q54158931 | Familial Amyotrophic Lateral Sclerosis. |
Q34547620 | Familial amyotrophic lateral sclerosis |
Q45342245 | Familial amyotrophic lateral sclerosis with Cys111Tyr mutation in Cu/Zn superoxide dismutase showing widespread Lewy body-like hyaline inclusions |
Q48611420 | Familial amyotrophic lateral sclerosis with an I104F mutation in the SOD1 gene: Multisystem degeneration with neurofilamentous aggregates and SOD1 inclusions |
Q26741250 | From animal models to human disease: a genetic approach for personalized medicine in ALS |
Q34479235 | Genetic overlap between apparently sporadic motor neuron diseases |
Q34509807 | Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics |
Q51107457 | Genetics of Amyotrophic Lateral Sclerosis. |
Q36573336 | Molecular biology of amyotrophic lateral sclerosis: insights from genetics |
Q37959310 | Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology |
Q89976497 | Mutations in Superoxide Dismutase 1 (Sod1) Linked to Familial Amyotrophic Lateral Sclerosis Can Disrupt High-Affinity Zinc-Binding Promoted by the Copper Chaperone for Sod1 (Ccs) |
Q36181355 | Ongoing trials in motor neurone disease |
Q21266563 | Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis |
Q74297199 | Progressive muscular atrophy variant of familial amyotrophic lateral sclerosis (PMA/ALS) |
Q33356197 | Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival |
Q92106562 | Redox Regulation of the Microcirculation |
Q44956628 | SOD1 gene mutations in ALS patients from British Columbia, Canada: clinical features, neurophysiology and ethical issues in management |
Q34613895 | Study of 962 patients indicates progressive muscular atrophy is a form of ALS. |
Q28246284 | Superoxyde dismutase 1 gene abnormalities in familial amyotrophic lateral sclerosis: phenotype/genotype correlations. The French experience and review of the literature |
Q77892135 | The genetic and molecular mechanisms of motor neuron disease |
Q38259758 | The phenotypic variability of amyotrophic lateral sclerosis |